IPO Details
Bidding Dates
20 Dec 24 - 24 Dec 24
Price Range ₹
372 - 391
Total Equity
₹ 333.71Cr
Lot Size
38
Exchange Status
BSE,NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
89.23×
Qualified Institutional Buyers
94.66×
Employees
19.92×
Retail Investors
89.23×
Total subscription Rate
93.41×
IPO Timeline
Offer start
20 Dec 2024
Offer end
24 Dec 2024
Allotment
26 Dec 2024
Refund initiation
27 Dec 2024
Demat transfer
27 Dec 2024
Listing
30 Dec 2024
Offer start
20 Dec 2024
Offer end
24 Dec 2024
Allotment
26 Dec 2024
Refund initiation
27 Dec 2024
Demat transfer
27 Dec 2024
Listing
30 Dec 2024
About Company
Established in December 2017, Senores Pharmaceuticals Limited focuses on developing and manufacturing pharmaceutical products for regulated markets such as the US, Canada, and the UK, while also catering to emerging markets. The company's diverse product portfolio includes tablets and capsules across key therapeutic areas, such as antibiotics, anti-fungal treatments, and critical care medications. As of September 30, 2024, they have launched 55 products and established partnerships with distributors and hospitals across India. Senores operates three dedicated R&D facilities in India and the US, with a US FDA-approved manufacturing facility based in Ahmedabad, Gujarat. The company also manufactures APIs and critical care injectables, serving 43 countries in emerging markets. Its competitive strengths include a robust R&D capability, a specialized product portfolio tailored for regulated markets, and long-term marketing agreements with pharmaceutical companies in the US, Canada, and the UK. Backed by an experienced management team, the company is well-positioned for growth in both regulated and emerging markets.
Year Founded
26-12-2017
Promotor Details
Sanjay Shaileshbhai Majmudar
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 66.67 | 45.76 |
| Share Capital | 22176079 | 21076079 |
Offer to Public
85,34,681.00 Cr
Highlights
- Ability to serve regulated markets like the US, Canada, and the UK through a US FDA-approved manufacturing facility.
- Distinct niche product portfolio developed in a short time for regulated markets.
- Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the UK.
- Presence in emerging markets with a strong portfolio, including specialty and complex products.
- Strong R&D capabilities driving a differentiated product portfolio.
Challenges
- Dependence on third-party marketing partners and distributors, with the risk of losing partners or facing financial instability, which could adversely affect business performance.
- Reliance on the growth of regulated markets, with a potential decrease in market growth or failure to adapt to changes, negatively impacting operations and financial performance.
- Risk of non-compliance with customer quality standards, leading to business loss, order cancellations, and warranty claims.
- Dependence on a few key customers for revenue, with the risk of reduced demand or contract terminations affecting cash flows and business stability.
- Negative cash flows from operating activities in recent fiscal years, potentially impacting future business operations and financial health.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2023 | 1,310.53 | 98.15 | 327.08 | 314.55 | 10.3114 |
| 2024 | 6,069.24 | 305.05 | 327.08 | 314.55 | 10.3114 |
| 2022 | 587.00 | 87.42 | 84.33 | 84.33 | 8.592 |
